Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report
Language English Country Czech Republic Media print-electronic
Document type Case Reports, Journal Article
PubMed
26725706
DOI
10.5507/bp.2015.061
Knihovny.cz E-resources
- Keywords
- esophageal melanoma, masitinib, targeted therapy,
- MeSH
- Benzamides MeSH
- Exons MeSH
- Fatal Outcome MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Melanoma drug therapy secondary MeSH
- Mutation genetics MeSH
- Esophageal Neoplasms drug therapy MeSH
- Brain Neoplasms drug therapy secondary MeSH
- Piperidines MeSH
- Proto-Oncogene Proteins c-kit genetics MeSH
- Pyridines MeSH
- Thiazoles therapeutic use MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Benzamides MeSH
- Protein Kinase Inhibitors MeSH
- masitinib MeSH Browser
- Piperidines MeSH
- Proto-Oncogene Proteins c-kit MeSH
- Pyridines MeSH
- Thiazoles MeSH
BACKGROUND: Malignant melanoma in the gastrointestinal tract may be primary or metastatic. Mucosal melanoma is a quite rare and aggressive disease, growing hidden and diagnosed with a certain delay which makes treatment difficult. CASE REPORT: The authors present the first patient with c-kit exon 11 mutated primary esophageal melanoma treated with oral tyrosine kinase inhibitor masitinib. A 55-year-old-man presented with esophageal melanoma metastising into visceral organs and to the brain. The patient showed objective and clinical significant therapeutic response to masitinib. After initiation of masitinib, dysphagia and odynophagia disappeared within 1 week. Following 1 month of treatment, computed tomography showed a regression in the number and size of brain metastatic lesions and regression in visceral lesions. This therapeutic response, despite the aggressive disease on treatment initiation, effectively enabled the patient to have 6 months of quality life. CONCLUSION: This report corroborates the plausibility of treating advanced melanoma carrying a mutation of KIT with masitinib. It also raises the question of masitinib treatment beyond progression. Additionally, the observed masitinib treatment effect on the brain suggests accumulation of therapeutically relevant concentration of masitinib in the central nervous system. This observation has possible ramifications for treatment of intracranial neoplasms.
Department of Clinical Oncology and Radiotherapy University Hospital in Hradec Kralove
Department of Clinical Oncology County Hospital Nachod Czech Republic
Department of Histopathology County Hospital Nachod
References provided by Crossref.org
